Related Experiment Video
Updated: Aug 18, 2026

Acute Myocardial Infarction in Rats
Published on: February 17, 2011
An update on acute myocardial infarction from recent clinical trials
1Duke Clinical Research Institute, Durham, NC 27705, USA.
Abstract:
Exploration of new strategies and therapies to improve survival and outcomes of acute myocardial infarction (AMI) continues. Recently published large clinical trials, including the long-term results from Grampian Region Early Anistreplase Trial, Global Use of Strategies to Open Occluded Coronary Arteries, and the Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes (GUSTO-)IIb angioplasty substudy, have helped to clarify the relative benefits of earlier treatment, the use of third-generation thrombolytic agents, and the use of primary angioplasty. Other, smaller trials such as Evaluation of c7E3 Fab in Preventing ischemic Complications of High-risk Angioplasty and intracoronary Stenting and Antithrombotic Regimen have stimulated thoughts about new adjunctive agents and devices, including platelet glycoprotein IIb/IIIa antagonists, primary stenting, and antioxidants. Both knowledge and therapies have advanced significantly in the past year, which should improve clinical outcomes of AMI in the near future.
Insights
New clinical trials and therapies are improving outcomes for acute myocardial infarction (AMI). Advances in early treatment, thrombolytic agents, angioplasty, and adjunctive therapies offer better survival for AMI patients.
Area of Science:
- Cardiology
- Interventional Cardiology
- Clinical Trials
Background:
- Acute myocardial infarction (AMI) management is evolving with ongoing research.
- Large clinical trials provide insights into optimal treatment strategies.
- Emerging adjunctive therapies and devices show promise for high-risk patients.
Purpose of the Study:
- To review recent advancements in acute myocardial infarction (AMI) therapies.
- To highlight the impact of new clinical trial data on patient outcomes.
- To discuss the role of novel agents and devices in AMI management.
Main Methods:
- Analysis of recently published large clinical trials (e.g., Grampian Region Early Anistreplase Trial, GUSTO-IIb).
- Review of smaller trials evaluating adjunctive therapies (e.g., Evaluation of c7E3 Fab in Preventing ischemic Complications of High-risk Angioplasty).
- Synthesis of evidence on early treatment, thrombolysis, angioplasty, stenting, and antioxidants.
Main Results:
- Earlier treatment, third-generation thrombolytic agents, and primary angioplasty demonstrate clear benefits.
- Platelet glycoprotein IIb/IIIa antagonists and primary stenting are key areas of investigation.
- Antioxidants are also being explored for their potential role in AMI management.
Conclusions:
- Significant advancements in knowledge and therapies are expected to improve AMI survival and outcomes.
- The integration of evidence from large and small trials is crucial for clinical practice.
- Continued research into novel adjunctive therapies and devices will further refine AMI treatment.
More Related Videos
14:35Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
05:41Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
Published on: December 16, 2022
Related Concept Videos
Myocarditis II: Clinical Features and Diagnostic Tests
Acute Coronary Syndrome I: Introduction
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
Acute Coronary Syndrome III: Diagnostic Studies
Acute Coronary Syndrome IV: Interprofessional Care
Acute Coronary Syndrome V: Nursing Management